Navigation Links
Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
Date:2/10/2012

BETHESDA, Md., Feb. 10, 2012 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that Dr. Claire Kruger, Chief Executive Officer, will present to investors as part of the LHA, Inc. Life Sciences & Medical Technologies Virtual Conference on Thursday, February 16, 2012, at 12:30 p.m. Eastern time.

The webcast of the Spherix presentation will be accessible live and for 30 days at www.spherix.com or the PrecisionIR event site http://www.investorcalendar.com/IC/CEPage.asp?ID=167333.

This virtual conference event includes 30-minute presentations with accompanying slides from eight industry leaders, and begins at 9:00 a.m. Eastern time.

About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis.  Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke.  Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.

Forward-Looking Statements
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934.  Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of our products, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop products may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission.  Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Announces Registered Direct Offering of $1.15 Million
2. Spherix Announces Successful Completion of Important Toxicology Study of SPX-106
3. Spherix Announces Third Quarter Financial Results
4. Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds
5. Spherix to Raise $1.25 Million in Private Placement
6. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
7. Spherix Announces Annual Shareholders Meeting Date
8. Spherix to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
9. Spherix Regains Compliance With NASDAQ Listing Rule
10. Spherix Announces First Quarter Financial Results
11. Spherix Announces Reverse Stock Split Effective May 6, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Fiberstar, Inc ., a global market ... Citri-Fi® 125. This natural citrus fiber is used to improve tomato-based food products by ... sauces, condiments and spreads. Today, more than ever, consumers connect ingredients to the foods ...
(Date:7/24/2017)... ... ... Charm Sciences, Inc. is pleased to announce the Charm® ROSA® Tetracycline-SL (Dilution ... (NCIMS) Laboratory Committee and Appendix N Committee as a drug residue test kit for ... voted at its annual meeting in April, 2015 to establish a pilot program to ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... the stock market news outlet had initiated coverage on Interpace Diagnostics. Interpace ... and identifies exposure, progression and risk analysis from specific cancers in humans. ...
(Date:7/20/2017)... ... 20, 2017 , ... Dr. Asher Kimchi, Founder and Chairman of the ... Awards at the 22nd World Congress on Heart Disease held in Vancouver, BC, Canada. ... the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with Co-Chairmen Dr. John A. ...
Breaking Biology Technology:
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
Breaking Biology News(10 mins):